Clinical trials: Spleen Disorder
Lymphoma, Prostate Cancer
AMG-479 in Treating Patients With Advanced Solid Tumors or Non-Hodgkin Lymphoma
RATIONALE: Monoclonal antibodies, such as AMG-479, can block cancer growth in different ways. Some block the ability of cancer cells to grow and spread.
- Conditions
- Lymphoma, Prostate Cancer, Sarcoma, Small Intestine Cancer
- Trial name
- NCT00562380
- Testing
- ganitumab, laboratory biomarker analysis, pharmacological study
- Where
- United States
- Volunteers
- 64 people
- Sponsor
- Amgen
Lymphoma, Unspecified Adult Solid Tumor, Protocol Specific
MP470 in Treating Patients With Unresectable or Metastatic Solid Tumor or Lymphoma
RATIONALE: MP470 may stop the growth of cancer cells by blocking some of the enzymes needed for cell growth. PURPOSE: This clinical trial is studying the side effects and best dose of MP470 in treating patients with unresectable…
- Trial name
- NCT00504205
- Testing
- multitargeted receptor tyrosine kinase inhibitor MP470, laboratory biomarker analysis, pharmacological study
- Where
- 2 sites in United States
- Volunteers
- 30 people
- Sponsor
- Astex Pharmaceuticals, Inc.
Brain and Central Nervous System Tumors, Breast Cancer
Yttrium Y 90 SMT 487 in Treating Patients With Refractory or Recurrent Cancer
RATIONALE: Radiolabeled drugs such as yttrium Y 90 SMT 487 can locate tumor cells and deliver tumor-killing substances to them without harming normal cells.
- Conditions
- Brain and Central Nervous System Tumors, Breast Cancer, Gastrointestinal Carcinoid Tumor, Islet Cell Tumor
- Trial name
- NCT00006368
- Testing
- yttrium Y 90-edotreotide
- Where
- United States
- Volunteers
- 60 people
- Sponsor
- Novartis Pharmaceuticals
Gall Bladder Disease, Bile Duct Diseases
AE05ML Device for ML Hem-o-lok Polymer Clip Delivery in Laparoscopic Surgical Procedures Observational Registery Study
This clinical registry study aims to evaluate the safety and effectiveness of the AE05ML device for ligating vessels and tissue structures during laparoscopic surgery using Hem-o-lok® Medium Large (ML) polymer clips.
- Conditions
- Gall Bladder Disease, Bile Duct Diseases, Acute Cholecystitis, Kidney
- Trial name
- AE05ML (NCT06364865)
- Testing
- laparoscopic procedure
- Where
- 3 sites in United States
- Volunteers
- 161 people
- Sponsor
- Teleflex
Cancer
Fentanyl Sublingual Spray in Treating Patients With Breakthrough Cancer Pain
This is a phase III, randomized, double-blind, placebo-controlled, multicenter study of the clinical response to fentanyl sublingual spray as a treatment for breakthrough cancer pain.
- Trial name
- NCT00538850
- Testing
- Fentanyl sublingual spray
- Where
- United States
- Volunteers
- 130 people
- Sponsor
- INSYS Therapeutics Inc
Lymphoma
SL-11047 in Treating Patients With Relapsed or Refractory Lymphoma
RATIONALE: Drugs used in chemotherapy, such as SL-11047, work in different ways to stop the growth of cancer cells, either by killing the cells or by stopping them from dividing.
- Trial name
- NCT00293488
- Testing
- polyamine analogue PG11047
- Where
- United States
- Volunteers
- 20 people
- Sponsor
- Progen Pharmaceuticals
Rheumatoid Arthritis
Ultrasound Neuroimmune Modulation in Adults With Rheumatoid Arthritis
This two-stage, multicenter clinical trial is designed to evaluate the feasibility, safety, and preliminary efficacy of splenic ultrasound stimulation to activate immune-neuromodulation (SUSTAIN) in patients with rheumatoid…
- Trial name
- SUSTAIN (NCT07293871)
- Testing
- Active treatment
- Where
- 3 sites in United States
- Volunteers
- 40 people
- Sponsor
- Surf Therapeutics
Rheumatoid Arthritis (RA)
At-home Ultrasound Localized Therapy for Rheumatoid Arthritis Study [At-home ULTRA Study]
The At-Home ULTRA Study will evaluate performance of the MINI system as indicated for the treatment of adults with active, moderate to severe rheumatoid arthritis who are inadequate responders or are intolerant to conventional…
- Trial name
- At-home ULTRA (NCT07163221)
- Testing
- Non-invasive ultrasound stimulation of the spleen - Treatment Setting 1, Non-invasive ultrasound stimulation of the spleen - Treatment Setting 2, Conventional Synthetic DMARD
- Where
- 5 sites in United States
- Volunteers
- 60 people
- Sponsor
- SecondWave Systems Inc.
Leukemia, Lymphoma
BL22 Immunotoxin in Treating Patients With Refractory Chronic Lymphocytic Leukemia, Prolymphocytic Leukemia, or Non-Hodgkin's Lymphoma
RATIONALE: BL22 immunotoxin can find tumor cells and kill them without harming normal cells. PURPOSE: This phase I trial is studying the side effects and best dose of BL22 immunotoxin in treating patients with refractory B-cell…
- Trial name
- NCT00126646
- Testing
- BL22 immunotoxin, antibody-drug conjugate therapy, immunotoxin therapy
- Where
- United States
- Volunteers
- 24 people
- Sponsor
- MedImmune LLC
Cancer
BCX-1777 in Treating Patients With Refractory Cancer
RATIONALE: BCX-1777 may stop the growth of cancer cells by blocking the enzymes necessary for their growth. PURPOSE: Phase I trial to study the effectiveness of BCX-1777 in treating patients who have refractory cancer.
- Trial name
- NCT00073944
- Testing
- forodesine hydrochloride
- Where
- United States
- Sponsor
- BioCryst Pharmaceuticals
Myelofibrosis (MF)
A Study Evaluating Tolerability and Efficacy of Navitoclax Alone or in Combination With Ruxolitinib in Participants With Myelofibrosis
This is a Phase 2 open-label, multicenter study evaluating tolerability and efficacy of navitoclax alone or when added to ruxolitinib in participants with myelofibrosis.
- Trial name
- REFINE (NCT03222609)
- Testing
- Ruxolitinib, Navitoclax
- Where
- 91 sites in United States, Australia and 12 more
- Volunteers
- 191 people
- Sponsor
- AbbVie
Metabolic Syndrome
Clinical Study on Wuling Powder in Treating Metabolic Syndrome of Spleen Deficiency and Dampness
In this study, a randomized, partially double-blind, controlled, multi-center clinical research method was used. A total of 4 groups were designed, namely, single decoction group, co-decoction group, powder group and simulation…
- Trial name
- NCT04812236
- Testing
- Wulingsan single decoction granules, Wulingsan co-decoction granules, Wuling Powder
- Volunteers
- 320 people
- Sponsor
- Jiangsu Famous Medical Technology Co., Ltd.
Myelofibrosis
A Study to Evaluate Single Agent Selinexor Versus Physician's Choice in Participants With Previously Treated Myelofibrosis
This is a Phase 2, multicenter, two-arm, open-label study to evaluate the safety and efficacy of selinexor versus treatment per physician's choice (PC) in participants with myelofibrosis (MF) who had at least 6 months of…
- Trial name
- NCT04562870
- Testing
- Selinexor, Physician's Choice Treatment
- Where
- 21 sites in United States, China and 5 more
- Volunteers
- 112 people
- Sponsor
- Karyopharm Therapeutics Inc
Lymphoma, Unspecified Adult Solid Tumor, Protocol Specific
VEGF Trap in Treating Patients With Relapsed or Refractory Solid Tumors or Non-Hodgkin's Lymphoma
RATIONALE: VEGF Trap may stop the growth of solid tumors or non-Hodgkin's lymphoma by stopping blood flow to the cancer. PURPOSE: Phase I trial to study the effectiveness of VEGF Trap in patients who have relapsed or refractory…
- Trial name
- NCT00036946
- Testing
- ziv-aflibercept
- Where
- United States
- Sponsor
- Regeneron Pharmaceuticals
B-cell Non-Hodgkins Lymphoma, Chronic Lymphocytic Leukemia
Study to Evaluate Safety and Tolerability of XmAb13676 (Plamotamab) in Patients With CD20-expressing Hematologic Malignancies
The purpose of this study is to determine the safety and tolerability of intravenous (IV) and subcutaneous (SC) administration of XmAb13676 and to determine the maximally tolerated dose (MTD) and/or recommended dose (RD).
- Trial name
- NCT02924402
- Testing
- XmAb13676
- Where
- 23 sites in United States, France and 2 more
- Volunteers
- 154 people
- Sponsor
- Xencor, Inc.
Leukemia, Lymphoma
Safety Study of Human Myeloid Progenitor Cells (CLT-008) After Cord Blood Transplant for Hematologic Malignancy
Ex vivo expanded human myeloid progenitor cells (hMPCs; CLT-008) have the potential to accelerate neutrophil recovery in patients receiving myeloablative conditioning as part of an umbilical cord blood transplant for hematologic…
- Conditions
- Leukemia, Lymphoma, Multiple Myeloma, Plasma Cell Neoplasm
- Trial name
- NCT00891137
- Testing
- human myeloid progenitor cells
- Where
- 8 sites in United States
- Volunteers
- 30 people
- Sponsor
- Cellerant Therapeutics
Lymphoma, Unspecified Adult Solid Tumor, Protocol Specific
VEGF Trap in Treating Patients With Solid Tumors or Non-Hodgkin's Lymphoma
RATIONALE: VEGF Trap may stop the growth of solid tumors or non-Hodgkin's lymphoma by stopping blood flow to the cancer. PURPOSE: Phase I trial to study the effectiveness of VEGF Trap in treating patients who have relapsed or…
- Trial name
- NCT00045266
- Testing
- ziv-aflibercept
- Where
- United States
- Sponsor
- Regeneron Pharmaceuticals
Primary Myelofibrosis, Post-polycythemia Vera Myelofibrosis
Pacritinib Versus Best Available Therapy to Treat Patients With Myelofibrosis and Thrombocytopenia
Phase 3, randomized, controlled study to evaluate the safety and efficacy of oral pacritinib compared to Best Available Therapy (BAT) in patients with thrombocytopenia and primary or secondary myelofibrosis.
- Conditions
- Primary Myelofibrosis, Post-polycythemia Vera Myelofibrosis, Post-essential Thrombocythemia Myelofibrosis
- Trial name
- PAC326 (NCT02055781)
- Testing
- Pacritinib, Best Available Therapy
- Where
- 122 sites in United States, Australia and 10 more
- Volunteers
- 311 people
- Sponsor
- CTI BioPharma
Meningococcal Disease
Safety and Immunogenicity of Novartis Meningococcal B Vaccine When Administered to Immunocompromised Children and Adolescents Compared to Healthy Subjects.
The study aims at evaluating the safety and immunogenicity of rMenB+OMV NZ when administered to subjects from 2 to 17 years of age with increased risk of meningococcal disease because either of primary or secondary complement…
- Trial name
- NCT02141516
- Testing
- rMenB+OMV
- Where
- 20 sites in Italy, Poland and 3 more
- Volunteers
- 239 people, healthy volunteers welcome
- Sponsor
- Novartis
Adult Nasal Type Extranodal NK/T-cell Lymphoma, Anaplastic Large Cell Lymphoma
MORAb-004 in Treating Young Patients With Recurrent or Refractory Solid Tumors or Lymphoma
This phase I trial studies the side effects and best dose of MORAb-004 in treating young patients with recurrent or refractory solid tumors or lymphoma.
- Conditions
- Adult Nasal Type Extranodal NK/T-cell Lymphoma, Anaplastic Large Cell Lymphoma, Angioimmunoblastic T-cell Lymphoma, Childhood Burkitt Lymphoma
- Trial name
- NCT01748721
- Testing
- anti-endosialin/TEM1 monoclonal antibody MORAb-004, pharmacological study, laboratory biomarker analysis
- Where
- 20 sites in United States
- Volunteers
- 27 people
- Sponsor
- Morphotek